ClinicalTrials.gg
CompletedNCT00442897Updated May 22, 2024Results posted

Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)

A Phase 4 interventional study of simvastatin (+) ezetimibe and Comparator: atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
229
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
36th of 97
229 · median 148
Started
2006
with 5 others
Phase 4
31 of 98
1 open now
Registered
23rd of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 36th largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2006, is one of 31 in phase 4, and was the 23rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

Evaluate the proportion of hyperlipaemic persons with known coronary heart disease achieving ldl-c goal as defined by the national cholesterol education program (NCEP) adult treatment panel (ATP) III guidelines

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Hypercholesterolaemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are naïve to lowering lipid agent
  • Patients who are treated with lowering lipid agents and had a for 4 weeks.

Exclusion criteria

Exclusion Criteria:

  • Impaired kidney function
  • Increased liver enzyme levels
  • Pregnant women
  • to ezetimibe and other statin agents
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    1

    Drug: simvastatin (+) ezetimibe

  • Active comparator
    2

    Drug: Comparator: atorvastatin

Interventions

  • Drugsimvastatin (+) ezetimibe

    Drug pages: Ezetimibe · Simvastatin

    simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)

    Also known as: MK0653A, Vytorin®

  • atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)

    Also known as: Lipitor®

06

What researchers measure

Primary outcomes

  1. Number of Participants Reaching the LDL-C (Low Density Lipoprotein-Cholesterol) Goal (< 100 mg/dl) After 6 Weeks of Treatment

    Primary objective is to evaluate the proportion of patients achieving LDL-C target \<100 mg/dl recommend in National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) after 6 weeks of treatment(vytorin 10/20 vs. atorvastatin 10 mg)

    Time frame: After 6 weeks of treatment

Secondary outcomes

  1. Number of Participants Reaching the LDL-C Goal (< 100 mg/dl) After 12 Weeks of Treatment

    If patients didn't achieve LDL-C \<100 mg/dl after 6 weeks of treatment, they received the double dosage of study drug for the next 6 weeks (vytorin 10/40 or atorvastatin 20 mg) and If achieved LDL-C \< 100 mg/dl, they received the same dosage of study drug for the next 6 weeks.

    Time frame: After 12 weeks of the treatment

07

Results

Posted Nov 9, 2009

Participant flow

Patient were recruited between September 2006 and May 2008.

Base Study (12 Week Follow-up)
Participant flow — Base Study (12 Week Follow-up)
MilestoneVytorinAtorvastatin
Started118111
Completed10199
Not completed1712
Withdrew: Adverse event10
Withdrew: Death01
Withdrew: Protocol violation73
Withdrew: Withdrawal by subject98
24 Weeks Follow-up (3 Centers)
Participant flow — 24 Weeks Follow-up (3 Centers)
MilestoneVytorinAtorvastatin
Started3534
Completed2928
Not completed66
Withdrew: Adverse event10
Withdrew: Lost to follow-up22
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject13

Outcome measures

PrimaryNumber of Participants Reaching the LDL-C (Low Density Lipoprotein-Cholesterol) Goal (< 100 mg/dl) After 6 Weeks of Treatment

Primary objective is to evaluate the proportion of patients achieving LDL-C target \<100 mg/dl recommend in National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) after 6 weeks of treatment(vytorin 10/20 vs. atorvastatin 10 mg)

Time frame:
After 6 weeks of treatment
Reported as:
Number · Participants
Number of Participants Reaching the LDL-C (Low Density Lipoprotein-Cholesterol) Goal (< 100 mg/dl) After 6 Weeks of Treatment
ParticipantsVytorinAtorvastatin
Number of Participants Reaching the LDL-C (Low Density Lipoprotein-Cholesterol) Goal (< 100 mg/dl) After 6 Weeks of Treatment8963
Statistical analysis
  • Vytorin vs Atorvastatin · Odds ratio (or): 3.714 · 95% CI 1.77 to 7.78Odds ratio was adjusted by baseline LDL strata.
SecondaryNumber of Participants Reaching the LDL-C Goal (< 100 mg/dl) After 12 Weeks of Treatment

If patients didn't achieve LDL-C \<100 mg/dl after 6 weeks of treatment, they received the double dosage of study drug for the next 6 weeks (vytorin 10/40 or atorvastatin 20 mg) and If achieved LDL-C \< 100 mg/dl, they received the same dosage of study drug for the next 6 weeks.

Time frame:
After 12 weeks of the treatment
Reported as:
Number · Participants
Number of Participants Reaching the LDL-C Goal (< 100 mg/dl) After 12 Weeks of Treatment
ParticipantsVytorinAtorvastatin
Number of Participants Reaching the LDL-C Goal (< 100 mg/dl) After 12 Weeks of Treatment8563
Statistical analysis
  • Vytorin vs Atorvastatin · Odds ratio (or): 2.579 · 95% CI 1.32 to 5.06Odds ratio was adjusted by baseline LDL strata.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vytorin—0/108 (0%)19/108 (17.6%)
Atorvastatin—5/103 (4.9%)22/103 (21.4%)
Most frequent serious events
Most frequent serious events
EventVytorinAtorvastatin
Acute myocardial infarctionCardiac disorders0/1083/103
Cardiogenic shockCardiac disorders0/1081/103
Ventricular tachycardiaCardiac disorders0/1081/103
Gastrointestinal haemorrhageGastrointestinal disorders0/1081/103
CholelithiasisHepatobiliary disorders0/1081/103
Thrombosis in deviceInjury, poisoning and procedural complications0/1081/103
ArthralgiaMusculoskeletal and connective tissue disorders0/1081/103
CoughRespiratory, thoracic and mediastinal disorders0/1081/103
Most frequent other events
Showing 10 of 39
Most frequent other events
EventVytorinAtorvastatin
Upper respiratory tract infectionInfections and infestations4/1080/103
NasopharyngitisInfections and infestations1/1082/103
Generalized oedemaGeneral disorders0/1082/103
MyalgiaMusculoskeletal and connective tissue disorders0/1082/103
Pain in extremityMusculoskeletal and connective tissue disorders0/1082/103
Blood creatine phosphokinase increasedInvestigations1/1082/103
HeadacheInfections and infestations2/1081/103
Transaminases increasedInvestigations2/1080/103
CystitisInfections and infestations0/1081/103
DysphasiaNervous system disorders0/1081/103

Baseline characteristics

Age, Continuous
Age, Continuous(years)VytorinAtorvastatinTotal
Mean60.89 ± 9.2861.74 ± 9.9461.30 ± 9.59
Sex: Female, Male
Sex: Female, Male(Participants)VytorinAtorvastatinTotal
Female5753110
Male6158119
Baseline Low Density Lipoprotein-Cholesterol (LDL-C) allocation strata
Baseline Low Density Lipoprotein-Cholesterol (LDL-C) allocation strata(Participants)VytorinAtorvastatinTotal
LDL-C 130-159mg/dl6461125
LDL-C 160-189mg/dl383169
LDL-C >=190mg/dl161834
LDL-C <130mg/dl011
Baseline values for Apolipoprotein B (Apo B)
Baseline values for Apolipoprotein B (Apo B)(mg/dL)VytorinAtorvastatinTotal
Mean113.23 ± 30.97110.63 ± 31.63111.97 ± 31.25
Baseline values for High-Density Lipoprotein Cholesterol (HDL-C)
Baseline values for High-Density Lipoprotein Cholesterol (HDL-C)(mg/dL)VytorinAtorvastatinTotal
Mean48.23 ± 10.2548.9 ± 13.0148.55 ± 11.65
Baseline values for LDL-C:HDL-C
Baseline values for LDL-C:HDL-C(Ratio)VytorinAtorvastatinTotal
Mean3.54 ± 1.133.54 ± 1.043.54 ± 1.08
Baseline values for Low-Density Lipoprotein Cholesterol(LDL-C)
Baseline values for Low-Density Lipoprotein Cholesterol(LDL-C)(mg/dL)VytorinAtorvastatinTotal
Mean164.11 ± 33.52162.56 ± 26.75163.36 ± 30.37
Baseline values for Non HDL-C
Baseline values for Non HDL-C(mg/dL)VytorinAtorvastatinTotal
Mean191.54 ± 38.25190.72 ± 31.11191.14 ± 34.88

6 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2007
First posted
Mar 5, 2007
Start
Sep 2006
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Nov 9, 2009
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00442897
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Mar 5, 2007
Start date
Sep 2006
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Nov 9, 2009
Last update
May 22, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Simvastatin

Start the discussion